


C²
Sub
E²

56. (Amended) A method of combating a viral infection in a subject in need of such treatment comprising administering to said subject an effective infection-combating amount of a compound of Formula III



wherein:


R₁ is a branched or unbranched, saturated or unsaturated C₆ to C₁₈ alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

X is selected from the group consisting of NHCO, CH₃NCO, CONH, CONCH₃, S, SO, SO₂, O, NH, and NCH₃;

R₂ is a branched or unbranched, saturated or unsaturated C₆ to C₁₄ alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

Y is selected from the group consisting of NHCO, CH₃NCO, CONH, CONCH₃, S, SO, SO₂, O, NH, and NCH₃; and

Z is a moiety of the Formula V,




wherein:

V is H or N₃;

W is H or F; or


V and W together are a covalent bond; and

B is a purinyl moiety of Formula VI



optionally substituted at position 2 with [=O] -OH, -SH, -NH₂, or halogen, [at position 4 with NH₂ or =O,] at position 6 with Cl, -NH₂, -OH, or C₁-C₃ alkyl, and at position 8 with Br or I; or

B is a pyrimidinyl moiety of Formula VII



C²
cont

substituted at position 4 with =O or NH₂ and optionally substituted at position 5 with halogen or C₁-C₃ saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen;
or a pharmaceutical salt thereof.

C³

alkyl.

58. (Amended) A method according to claim 56, wherein R₁ is unbranched C₈

C¹
cont

alkyl.

59. (Amended) A method according to claim 56, wherein R₁ is unbranched C₁₀

60. (Amended) A method according to claim 56, wherein R₁ is unbranched C₁₂

alkyl.

C⁴

alkyl.

62. (Amended) A method according to claim 56, wherein R₂ is unbranched C₈

alkyl.

63. (Amended) A method according to claim 56, wherein R₂ is unbranched C₁₀

alkyl.


64. (Amended) A method according to claim 56, wherein R₂ is unbranched C₁₂

65. (Amended) A method according to claim 56, wherein X is [NCO] NHCO.


C⁵
cont
E³

95. (Amended) A compound of Formula III

C5-
E3
cont




wherein: R_1 is a branched or unbranched, saturated or unsaturated C_6 to C_{18} alkyl group optionally substituted from 1 to 5 times with $-\text{OH}$, $-\text{COOH}$, oxo, amine, or substituted or unsubstituted aromatic;
 X is selected from the group consisting of NHCO , CH_3NCO , CONH , CONCH_3 , S , SO , SO_2 , O , NH , and NCH_3 ;
 R_2 is a branched or unbranched, saturated or unsaturated C_6 to C_{14} alkyl group optionally substituted from 1 to 5 times with $-\text{OH}$, $-\text{COOH}$, oxo, amine, or substituted or unsubstituted aromatic;
 Y is selected from the group consisting of NHCO , CH_3NCO , CONH , CONCH_3 , S , SO , SO_2 , O , NH , and NCH_3 ; and
 Z is a moiety of the Formula V,



wherein: V is H or N_3 ;
 W is H or F ; or
 V and W together are a covalent bond; and

C5
E3
cont


B is a purinyl moiety of Formula VI



(VI)

optionally substituted at position 2 with [=O], -OH, -SH, -NH₂, or halogen, [at position 4 with NH₂ or =O,] at position 6 with Cl, -NH₂, -OH, or C₁-C₃ alkyl, and at position 8 with Br or I; or

B is a pyrimidinyl moiety of Formula VII




(VII)

substituted at position 4 with =O or NH₂ and optionally substituted at position 5 with halogen or C₁-C₃ saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen.

C6

101. (Amended) A method of combating tumors in a subject in need of such treatment comprising administering to said subject an effective amount of a compound of Formula III

C6




wherein: R_1 is a branched or unbranched, saturated or unsaturated C_6 to C_{18} alkyl group optionally substituted from 1 to 5 times with $-\text{OH}$, $-\text{COOH}$, oxo, amine, or substituted or unsubstituted aromatic;

X is selected from the group consisting of NHCO , CH_3NCO , CONH , CONCH_3 , S , SO , SO_2 , O , NH , and NCH_3 ;

R_2 is a branched or unbranched, saturated or unsaturated C_6 to C_{14} alkyl group optionally substituted from 1 to 5 times with $-\text{OH}$, $-\text{COOH}$, oxo, amine, or substituted or unsubstituted aromatic;

Y is selected from the group consisting of NHCO , CH_3NCO , CONH , CONCH_3 , S , SO , SO_2 , O , NH , and NCH_3 ; and

Z is a moiety of the Formula V,




wherein: V is H or N_3 ;

W is H or F ; or

V and W together are a covalent bond; and

C6


B is a purinyl moiety of Formula VI



(VI)

optionally substituted at position 2 with [=O] -OH, -SH, -NH₂, or halogen, [at position 4 with NH₂ or =O,] at position 6 with Cl, -NH₂, -OH, or C₁-C₃ alkyl, and at position 8 with Br or I; or

B is a pyrimidinyl moiety of Formula VII



(VII)

substituted at position 4 with =O or NH₂ and optionally substituted at position 5 with halogen or C₁-C₃ saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen;

or a pharmaceutical salt thereof.